{"id":26389,"date":"2024-09-07T03:06:01","date_gmt":"2024-09-06T21:36:01","guid":{"rendered":"https:\/\/vajiramandravi.com\/current-affairs\/?p=26389"},"modified":"2025-10-15T12:32:25","modified_gmt":"2025-10-15T07:02:25","slug":"bpalm-regimen","status":"publish","type":"post","link":"https:\/\/vajiramandravi.com\/current-affairs\/bpalm-regimen\/","title":{"rendered":"What is the BPaLM Regimen?"},"content":{"rendered":"<h2><strong>About BPaLM Regimen:<\/strong><\/h2>\n<ul>\n<li>It is a <strong>new treatment regimen against multi-drug-resistant tuberculosis<\/strong> (MDR-TB).<\/li>\n<li>It was introduced <strong>by the Union Health Ministry under<\/strong> its <strong>National TB Elimination Program (NTEP).<\/strong><\/li>\n<li><strong>Composition<\/strong>: The regimen <strong>combines four drugs<\/strong>\u2014<strong>Bedaquiline, Pretomanid, Linezolid<\/strong>, and <strong>optionally Moxifloxacin<\/strong>.<\/li>\n<li>This regimen includes a <strong>new anti-TB drug<\/strong> called <strong>Pretomanid<\/strong>, which was earlier approved and <strong>licensed for use in India by<\/strong> the Central Drugs Standard Control Organization (<strong>CDSCO<\/strong>).<\/li>\n<li><strong>Efficacy:<\/strong>\n<ul>\n<li>The BPaLM regimen is a <strong>safer and more effective<\/strong> treatment option compared to traditional MDR-TB treatments.<\/li>\n<li>It is an <strong>all-oral regimen<\/strong> with a <strong>low overall pill burden<\/strong>, which makes it patient-friendly.<\/li>\n<li>It can <strong>cure drug-resistant TB in just six months<\/strong>, <strong>compared to<\/strong> the <strong>previous treatment duration of<\/strong> up to <strong>20 months<\/strong>, and is associated with <strong>fewer side effects.<\/strong><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><strong>National TB Elimination Program (NTEP):<\/strong><\/p>\n<ul>\n<li>It is a <strong>public health initiative<\/strong> of the Government of India that organizes the country\u2019s tuberculosis elimination efforts.\u00a0<\/li>\n<li>It has set an <strong>ambitious goal of eradicating TB by 2025.<\/strong><\/li>\n<li>NTEP is a <strong>centrally sponsored scheme<\/strong> implemented <strong>under<\/strong> the aegis of the <strong>National Health Mission <\/strong>with resource sharing between the State Governments and the Central Government.<\/li>\n<li>It is <strong>based on the daily DOTS<\/strong> (<strong>Directly Observed Treatment with short-course chemotherapy) strategy.<\/strong>\n<ul>\n<li>The DOTS strategy <strong>ensures<\/strong> that infectious TB patients are diagnosed and treated effectively till cure, by <strong>ensuring availability of the full course of drugs<\/strong> and a <strong>system for monitoring patientcompliance<\/strong> to the treatment.<\/li>\n<\/ul>\n<\/li>\n<li>The program provides various <strong>free-of-cost, quality tuberculosis diagnosis and treatment<\/strong> services across the country.<\/li>\n<li><strong>NI-KSHAY Portal:<\/strong> NI-KSHAY (Ni=End, Kshay=TB) is the web enabled p<strong>atient management system for TB control<\/strong> under the National Tuberculosis Elimination Programme (NTEP).<\/li>\n<\/ul>\n<hr \/>\n<h3><strong>Q1<\/strong>: What is the Central Drugs Standard Control Organization (CDSCO)?<\/h3>\n<p>It is the National Regulatory Authority (NRA) of India for the medical devices industry under the provisions of the Drugs &amp; Cosmetics Rules. It works under the Ministry of Health &amp; Family Welfare. Drugs Controller General of India (DCGI) is the head of the CDSCO.<\/p>\n<p><strong>Source: <\/strong><a href=\"https:\/\/timesofindia.indiatimes.com\/india\/government-nod-to-6-month-therapy-for-drug-resistant-tb\/articleshow\/113137785.cms\" target=\"_blank\" rel=\"nofollow noopener\">Government nod to 6-month therapy for drugresistant TB<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>BPaLM Regimen is a new treatment regimen against multi-drug-resistant tuberculosis (MDR-TB).<\/p>\n","protected":false},"author":5,"featured_media":26390,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":{"0":"post-26389","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-upsc-prelims-current-affairs","8":"no-featured-image-padding"},"acf":[],"_links":{"self":[{"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/posts\/26389","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/comments?post=26389"}],"version-history":[{"count":0,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/posts\/26389\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/media\/26390"}],"wp:attachment":[{"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/media?parent=26389"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/categories?post=26389"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/tags?post=26389"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}